Aspirin

Platelets

Volumn , Issue , 2013, Pages 1099-1115

  Patrono, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882700453     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00053-5     Document Type: Chapter

References (105)

1. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232-235.
2. Ferreira S.H., Moncada S., Vane J.R. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol 1971, 231:237-239.
3. Smith J.B., Willis A.L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971, 231:235-237.
4. Hamberg M., Samuelsson B. Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc Natl Acad Sci USA 1973, 70:899-903.
5. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975, 72:2994-2998.
6. Roth G.J., Majerus P.W. The mechanism of the effect of aspirin on human platelets. Acetylation of a particulate fraction protein. J Clin Invest 1975, 56:624-632.
7. Roth G.J., Stanford N., Majerus P.W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975, 72:3073-3076.
8. Patrono C., Ciabattoni G., Pinca E., et al. Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980, 17:317-327.
9. 2 in man. Identification of twenty urinary metabolites. J Biol Chem 1981, 256:8384-8393.
10. Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982, 69:1366-1372.
11. FitzGerald G.A., Oates J.A., Hawiger J., et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983, 71:676-688.
12. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988, 2:349-360. ISIS-2 Collaborative Group.
13. Patrono C., García Rodríguez L.A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353:2373-2383.
14. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996, 271:33157-33160.
15. 2 synthase. Nature Struct Biol 1995, 2:637-643.
16. Bala M., Chin C.N., Logan A.T., et al. Acetylation of prostaglandin H2 synthases by aspirin is regulated by the redox state of the enzymes. Biochem Pharmacol 2008, 75:1472-1481.
17. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999, 96:272-277.
18. 2 but not systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991, 325:1137-1141.
19. Topper J.N., Cai J., Falb D., Gimbrone M.A. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996, 93:10417-10422.
20. Murata T., Ushikubi F., Matsuoka T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388:678-682.
21. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308.
22. Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006, 116:4-15.
23. Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. Goodman & Gilman's The Pharmacological Basis of Therapeutics. L Brunton, B. Chabner, B Knollman Editors, 12th ed. New York: McGraw-Hill, 2011;959-1004.
24. Pedersen A.K., FitzGerald G.A. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclo-oxygenase. N Engl J Med 1984, 311:1206-1211.
25. Cox D., Maree A.O., Dooley M., Conroy R., Byrne M.F., Fitzgerald D.J. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006, 37:2153-2158.
26. Zhou G., Marathe G.K., Willard B., McIntyre T.M. Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. J Biol Chem 2011, 286:34820-34829.
27. Burch J.W., Stanford P.W., Majerus P.W. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1979, 61:314-319.
28. Demers L.M., Budin R., Shaikh B. The effects of aspirin on megakaryocyte prostaglandin production. Proc Soc Exp Biol Med 1980, 163:24-29.
29. Rocca B., Secchiero P., Ciabattoni G., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002, 99:7634-7639.
30. Dragani A., Pascale S., Recchiuti A., et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-insensitive essential thrombocythemia: implications for antiplatelet therapy. Blood 2010, 115:1054-1061.
31. Pascale S, Petrucci G, Dragani, A, et al. Aspirin insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595-603.
32. Reilly I.A.G., FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987, 69:180-186.
33. Santilli F., Rocca B., De Cristofaro R., et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. J Am Coll Cardiol 2009, 53:667-677.
34. Menè P., Pugliese F., Patrono C. The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin Nephrol 1995, 15:244-252.
35. Pierucci A., Simonetti B.M., Pecci G., et al. Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N Engl J Med 1989, 320:421-425.
36. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345:433-442.
37. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
38. Al-Khadra A.S., Salem D.N., Rand W.M., et al. Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol 1998, 31:419-425.
39. Latini R., Tognoni G., Maggioni A.P., et al. Clinical effects of early ACE inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: meta-analysis of individual data from nearly 96,000 randomized patients. J Am Coll Cardiol 2000, 35:1801-1807.
40. Zanchetti A., Hansson L., Leonetti G., et al. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens 2002, 20:1015-1022.
41. Teo K.K., Yusuf S., Pfeffer M., et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002, 360:1037-1043.
42. Mahaffey K.W., Wojdyla D.M., Carroll K., et al. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2011, 124:544-554.
43. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemostas 2003, 1:1710-1713.
44. Davì G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482-2494.
45. th Edition). Chest 2008, 133:199S-233S.
46. Schwartz K.A., Schwartz D.E., Ghosheh K., Reeves M.J., Barber K., DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005, 95:973-975.
47. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006, 47:27-33.
48. Frelinger A.L., Li Y., Linden M.D., et al. Aspirin "resistance": role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008, 6:2035-2044.
49. Rocca B., Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005, 8:1597-1602.
50. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809-1817.
51. Capone M.L., Sciulli M.G., Tacconelli S., et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005, 45:1295-1301.
52. Anzellotti P., Capone M.L., Jeyam A., et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 2011, 63:850-859.
53. Renda G., Tacconelli S., Capone M.L., et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006, 80:264-274.
54. Lordkipanidzé M., Diodati J.G., Palisaitis D.A., Schampaert E., Turgeon J., Pharand C. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb Res 2011, 128:47-53.
55. Mattiello T., Guerriero R., Lotti L.V., et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol 2011, 58:752-761.
56. Krasopoulos G., Brister S.J., Beattie W.S., Elliot R.F., Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008, 336:195-198.
57. Antithrombotic Trialists' (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860.
58. Baroletti S., Dell'Orfano H. Medication adherence in cardiovascular disease. Circulation 2010, 121:1455-1458.
59. Frelinger A.L., Li Y., Linden M.D., et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009, 120:2586-2596.
60. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., Yusuf S. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650-1655.
61. Eikelboom J.W., Hankey G.J., Thom J., et al. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008, 118:1705-1712.
62. 12 inhibitors. Circulation 2010, 121:171-179.
63. Patrono C., Andreotti F., Arnesen H., et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011, 32:2922-2932.
64. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
65. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010, 363:930-942. CURRENT-OASIS 7 Investigators.
66. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002, 324:71-86.
67. International Stroke Trial Collaborative Group The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997, 349:1569-1581.
68. CAST (Chinese Acute Stroke Trial) Collaborative Group CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997, 349:1641-1649.
69. Van Kooten F., Ciabattoni G., Patrono C., Schmitz P.I.M., Van Gijn J., Koudstaal P.J. Evidence for episodic platelet activation in acute ischemic stroke. Stroke 1994, 25:278-281.
70. th Edition). Chest 2008, 133:776S-814S.
71. th Edition). Chest 2008, 133:630S-669SS.
72. Fowkes F.G., Price J.F., Stewart M.C., et al. Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010, 303:841-848.
73. Ogawa H., Nakayama M., Morimoto T., et al. for the JPAD Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. A randomized controlled trial. JAMA 2008, 300:2134-2141.
74. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:1030-1036.
75. Rothwell P.M., Proce J.F., Fowkes F.G., et al. Short-term effects of daily aspirin on risks of cancer and non-vascular death: analysis of the time-course of risks and benefits in randomised controlled trials. Lancet 2012, 379(9826):1602-1612.
76. Rothwell P.M., Wilson M., Elwin C.E., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
77. Rothwell P.M., Fowkes F.G.R., Belch J.F.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
78. Patrono C., Rocca B. The future of antiplatelet therapy in cardiovascular disease. Ann Rev Med 2010, 61:49-61.
79. The Dutch TIA Trial Study Group A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991, 325:1261-1266.
80. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13.
81. García Rodríguez L.A., Lin K.J., Hernández-Díaz S., Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011, 123:1108-1115.
82. Bousser M.G., Amarenco P., Chamorro A., et al. PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011, 377:2013-2022.
83. García Rodríguez L.A., Hernández-Díaz S., de Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001, 52:563-571.
84. Kelly J.P., Kaufman D.W., Jurgelon J.M., Sheehan J., Koff R.S., Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996, 348:1413-1416.
85. De Abajo F.J., García Rodríguez L.A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001, 1:1.
86. Chan F.K., Chung S.C.S., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
87. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005, 352:238-244.
88. Lai K.C., Chu K.M., Hui W.M., et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006, 4:860-865.
89. Iso H., Hennekens C.H., Stampfer M.J., et al. Prospective study of aspirin use and risk of stroke in women. Stroke 1999, 30:1764-1771.
90. U.S.Prevention Services Task Force Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 150:396-404.
91. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):S1-113.
92. U.S.Prevention Services Task Force Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer. U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007, 146:361-364.
93. Thun M.J., Jacobs E.J., Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012, 9(5):259-267.
94. Flossman E., Rothwell P.M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369:1603-1613.
95. Thun M., Henley S., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94:252-266.
96. Chulada P.C., Thompson M.B., Mahler J.F., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Research 2000, 60:4705-4708.
97. Sandler R.S., Halabi S., Baron J.A., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348:883-890.
98. Baron J.A., Cole B.F., Sandler R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003, 348:891-899.
99. Benamouzig R., Deyra J., Martin A., et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003, 125:328-336.
100. Logan R.F.A., Grainge M.J., Shepherd V.C., Armitage N.C., Muir K.R. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008, 134:29-38.
101. Baron J.A., Sandler R.S., Bresalier R.S., et al. APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131:1674-1682.
102. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873-884.
103. Nelson M.R., Reid C.M., Ames D.A., et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008, 189:105-109.
104. Patrono C., Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol 2008, 28:25S-32S.
105. Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012;10:1220-30.